Evidence map›Paper›PMID 38972247›Full record

ArticleClinics (Sao Paulo, Brazil)2024

Transcriptomics analysis identified ezrin as a potential druggable target in cervical and gastric cancer cells.

Maria Fernanda Lopes Carvalho, Carolina Santana Calicchio, Bruna Oliveira de Almeida, Livia Bassani Lins de Miranda, Jean Carlos Lipreri da Silva, Keli Lima, João Agostinho Machado-Neto

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinics (Sao Paulo, Brazil), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Maria Fernanda Lopes CarvalhoDepartment of Pharmacology, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP, Brazil.
Carolina Santana CalicchioDepartment of Pharmacology, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP, Brazil.
Bruna Oliveira de AlmeidaDepartment of Pharmacology, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP, Brazil.
Livia Bassani Lins de MirandaDepartment of Pharmacology, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP, Brazil.
Jean Carlos Lipreri da SilvaDepartment of Pharmacology, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP, Brazil.
Keli LimaDepartment of Pharmacology, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP, Brazil; Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Hematology Division, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil.
João Agostinho Machado-NetoDepartment of Pharmacology, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, SP, Brazil. Electronic address: jamachadoneto@usp.br.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveCancer genomics and transcriptomics studies have provided a large volume of data that enables to test of hypotheses based on real data from cancer patients. Ezrin (encoded by the EZR gene) is a highly expressed protein in cancer that contributes to linking the actin cytoskeleton to the cell membrane and signal transduction pathways involved in oncogenesis and disease progression. NSC305787 is a pharmacological ezrin inhibitor with potential antineoplastic effects. In the present study, the authors prospected EZR mRNA levels in a pan-cancer analysis and identified potential cancers that could benefit from anti-EZR therapies.

methodsThis study analyzed TCGA data for 32 cancer types, emphasizing cervical squamous cell carcinoma and stomach adenocarcinoma. It investigated the impact of EZR transcript levels on clinical outcomes and identified differentially expressed genes. Cell lines were treated with NSC305787, and its effects were assessed through various cellular and molecular assays.

resultsEZR mRNA levels are highly expressed, and their expression is associated with biologically relevant molecular processes in cervical squamous carcinoma and stomach adenocarcinoma. In cellular models of cervical and gastric cancer, NSC305787 reduces cell viability and clonal growth (p < 0.05). Molecular analyses indicate that the pharmacological inhibition of EZR induces molecular markers of cell death and DNA damage, in addition, to promoting the expression of genes associated with apoptosis and inhibiting the expression of genes related to survival and proliferation.

conclusionThe present findings provide promising evidence that ezrin may be a molecular target in the treatment of cervical and gastric carcinoma.

Indexed as

AdenocarcinomaCytoskeletal ProteinsGene Expression ProfilingStomach NeoplasmsUterine Cervical NeoplasmsAntineoplastic AgentsApoptosisCarcinoma, Squamous CellCell Line, TumorCell ProliferationCell SurvivalEzrinFemaleGene Expression Regulation, NeoplasticHumansRNA, MessengerAntineoplastic AgentsCytoskeletal ProteinsEzrinRNA, MessengerCervical cancerEzrinGastric cancerPharmacologyTranscriptomics

Identifiers

PMID38972247
PMCPMC11276928

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.